• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study.

作者信息

Marchesini Gessica, Nadali Gianpaolo, Facchinelli Davide, Candoni Anna, Cattaneo Chiara, Cuccaro Annarosa, Fanci Rosa, Farina Francesca, Lessi Federica, Visentin Andrea, Marchesi Francesco, Prezioso Lucia, Spolzino Angelica, Tisi Maria Chiara, Trastulli Fabio, Verga Luisa, Dargenio Michela, Busca Alessandro, Pagano Livio

机构信息

Haematology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.

Division of Haematology and Stem Cell Transplantation, University Hospital of Udine, Udine, Italy.

出版信息

Leuk Lymphoma. 2020 Dec;61(12):3002-3005. doi: 10.1080/10428194.2020.1786562. Epub 2020 Jul 1.

DOI:10.1080/10428194.2020.1786562
PMID:32611212
Abstract
摘要

相似文献

1
Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study.用维布妥昔单抗治疗的淋巴增殖性疾病患者的感染：SEIFEM多中心回顾性研究
Leuk Lymphoma. 2020 Dec;61(12):3002-3005. doi: 10.1080/10428194.2020.1786562. Epub 2020 Jul 1.
2
Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies.本妥昔单抗治疗原发性免疫缺陷中淋巴增殖性疾病的安全性和有效性。
Haematologica. 2020 Sep 1;105(9):e461-464. doi: 10.3324/haematol.2019.230276.
3
Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.单药本妥昔单抗作为严重肝功能损害的霍奇金淋巴瘤患者的一线治疗：两例报告
Ann Hematol. 2023 Oct;102(10):2973-2975. doi: 10.1007/s00277-023-05390-4. Epub 2023 Jul 31.
4
Severe Progressive Mycobacterium avium Complex Infection Associated With Brentuximab Vedotin Therapy.与维布妥昔单抗治疗相关的严重进行性鸟分枝杆菌复合群感染
J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):371-373. doi: 10.1093/jpids/piy109.
5
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.接受本妥昔单抗治疗的患者发生胰腺炎：一种先前未被认识到的严重不良事件。
Blood. 2014 May 1;123(18):2895-7. doi: 10.1182/blood-2014-03-561878.
6
Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report.用于难治性霍奇金淋巴瘤的本妥昔单抗治疗后发生急性胰腺炎：一例报告
Drugs R D. 2014 Mar;14(1):9-11. doi: 10.1007/s40268-014-0036-x.
7
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.接受维布妥昔单抗治疗的霍奇金淋巴瘤患者发生严重的周围运动神经病。
Leuk Lymphoma. 2013 Oct;54(10):2318-21. doi: 10.3109/10428194.2013.773997. Epub 2013 Mar 8.
8
Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.对一名难治性霍奇金淋巴瘤患者进行的本妥昔单抗脱敏治疗
Eur J Haematol. 2015 Oct;95(4):361-4. doi: 10.1111/ejh.12570. Epub 2015 May 6.
9
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.本妥昔单抗维迪昔联合 ABVD 或 AVD 方案用于治疗初诊霍奇金淋巴瘤患者的 1 期、开放标签、剂量递增研究。
Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.
10
Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin.儿童复发或难治性霍奇金淋巴瘤患者接受 Brentuximab vedotin 治疗后的肺部毒性。
Br J Haematol. 2018 Oct;183(2):251-256. doi: 10.1111/bjh.15586. Epub 2018 Sep 10.

引用本文的文献

1
Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin's Lymphoma: A Case Report and Review of the Literature.经典型霍奇金淋巴瘤患者接受A+AVD治疗后发生内脏利什曼病：一例报告并文献复习
J Clin Med. 2024 Sep 27;13(19):5756. doi: 10.3390/jcm13195756.
2
Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients.自体造血干细胞移植受者中的耶氏肺孢子菌感染。
Bone Marrow Transplant. 2023 Apr;58(4):446-451. doi: 10.1038/s41409-022-01906-0. Epub 2022 Dec 22.
3
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
新型靶向药物治疗的淋巴增殖性疾病患者的严重感染：一项多中心真实世界研究。
Cancer Med. 2021 Nov;10(21):7629-7640. doi: 10.1002/cam4.4293. Epub 2021 Sep 23.